TY - JOUR
T1 - Point Prevalence Survey of Antibiotic Use in Level 1 hospitals in Zambia
T2 - Future Prospects for Antimicrobial Stewardship Programs
AU - Mudenda, Steward
AU - Lubanga, Adriano Focus
AU - Jamshed, Shazia
AU - Biemba, Bibian
AU - Sakala, Racheal
AU - Chiyabi, Mervis
AU - Kavubya, Lorraine
AU - Milambo, Linda Twaambo
AU - Bumbangi, Flavien Nsoni
AU - Chizimu, Joseph Yamweka
AU - Yamba, Kaunda
AU - Wesangula, Evelyn
AU - Chigome, Audrey
AU - Kalungia, Aubrey Chichonyi
AU - Sefah, Israel Abebrese
AU - Mustafa, Zia U.I.
AU - Massele, Amos Yared
AU - Saleem, Zikria
AU - Mutemwa, Richard
AU - Kazonga, Eustarckio
AU - Sartelli, Massimo
AU - Meyer, Johanna Catharina
AU - Muma, John Bwalya
AU - Chilengi, Roma
AU - Godman, Brian
N1 - Publisher Copyright:
© 2025 Mudenda et al.
PY - 2025
Y1 - 2025
N2 - Introduction: The inappropriate prescribing and use of antibiotics have contributed to the emergence and spread of antimicrobial resistance (AMR). In Zambia, there is a paucity of information on the prescribing patterns and use of antibiotics among hospitalized patients in level 1 hospitals. This study investigated antibiotic use in five level 1 hospitals in Lusaka, Zambia. Methods: This cross-sectional study utilized the World Health Organization (WHO) Point Prevalence Survey (PPS) methodology among in-patients admitted in level 1 hospitals before 08:00 a.m. on the survey day in August 2024. Data were analysed using IBM SPSS version 23.0. Results: The prevalence of antibiotic use among inpatients was 59.0%, with ceftriaxone being the most prescribed. Antibiotics were prescribed mainly for paediatrics and male inpatients. This study found that 53.0% of prescribed antibiotics were from the Access group while 38.2% were from the Watch group of the World Health Organization Access, Watch, and Reserve (AWaRe) classification. Adherence to national treatment guidelines was 36.0%, with most antibiotics prescribed empirically without evidence of culture and sensitivity tests. Conclusion: This study found a high use of antibiotics and low adherence to treatment guidelines in level 1 hospitals in Lusaka, Zambia. The findings of this study demonstrate the need to establish and strengthen antimicrobial stewardship programs and strengthen laboratory capacity to aid clinicians in diagnosing, treating, and managing patients across level 1 hospitals in Zambia.
AB - Introduction: The inappropriate prescribing and use of antibiotics have contributed to the emergence and spread of antimicrobial resistance (AMR). In Zambia, there is a paucity of information on the prescribing patterns and use of antibiotics among hospitalized patients in level 1 hospitals. This study investigated antibiotic use in five level 1 hospitals in Lusaka, Zambia. Methods: This cross-sectional study utilized the World Health Organization (WHO) Point Prevalence Survey (PPS) methodology among in-patients admitted in level 1 hospitals before 08:00 a.m. on the survey day in August 2024. Data were analysed using IBM SPSS version 23.0. Results: The prevalence of antibiotic use among inpatients was 59.0%, with ceftriaxone being the most prescribed. Antibiotics were prescribed mainly for paediatrics and male inpatients. This study found that 53.0% of prescribed antibiotics were from the Access group while 38.2% were from the Watch group of the World Health Organization Access, Watch, and Reserve (AWaRe) classification. Adherence to national treatment guidelines was 36.0%, with most antibiotics prescribed empirically without evidence of culture and sensitivity tests. Conclusion: This study found a high use of antibiotics and low adherence to treatment guidelines in level 1 hospitals in Lusaka, Zambia. The findings of this study demonstrate the need to establish and strengthen antimicrobial stewardship programs and strengthen laboratory capacity to aid clinicians in diagnosing, treating, and managing patients across level 1 hospitals in Zambia.
KW - Point Prevalence Survey
KW - Zambia
KW - antibiotic use
KW - antimicrobial resistance
KW - antimicrobial stewardship
UR - http://www.scopus.com/inward/record.url?scp=85218768839&partnerID=8YFLogxK
U2 - 10.2147/IDR.S509522
DO - 10.2147/IDR.S509522
M3 - Article
C2 - 39975588
AN - SCOPUS:85218768839
SN - 1178-6973
VL - 18
SP - 887
EP - 902
JO - Infection and Drug Resistance
JF - Infection and Drug Resistance
ER -